Biogen favored to win against Icahn in proxy fight
BOSTON (Reuters) - Shareholders of Biogen Idec Inc will meet shortly to decide whether one of the world’s biggest and oldest biotechnology companies should remain independent or be put up for sale by billionaire investor Carl Icahn.
National Center for Biotechnology Information
U.S. government-funded national resource for molecular biology information. Access to many public databases and other references, including the draft human genome.
Designer eggs produced with lower cholesterol content
Singapore - Designer eggs containing qualities of a rare Chinese herb have been produced in Singapore with 30 per cent less cholesterol than normal chicken eggs, the developers claimed in a published report Monday. AP Nutripharm, a biotechnology firm…
Microcosm: E. coli and the New Science of Life
•Within days of being born, we are infected with billions of E. coli. They will inhabit each and every one of us until we die. E. coli is notorious for making people gravely ill, but engineered strains of the bacteria save millions of lives each year.
•Despite its microscopic size, E.coli contains more than four thousand genes that operate a staggeringly sophisticated network of millions of molecules.
•Scientists are rebuilding E. coli from the ground up, redefining our understanding of life on Earth.
In the tradition of classics like Lewis Thomas’s Lives of a Cell, Carl Zimmer has written a fascinating and utterly accessible investigation of what it means to be alive. Zimmer traces E. coli’s remarkable history, showing how scientists used it to discover how genes work and then to launch the entire biotechnology industry. While some strains of E. coli grab headlines by causing deadly diseases, scientists are retooling the bacteria to produce everything from human insulin to jet fuel.
Microcosm is the story of the one species on Earth that science knows best of all. It’s also a story of life itself–of its rules, its mysteries, and its future.
Author: Carl Zimmer
Hardcover: 256 pages
Company: Pantheon (2008-05-06) (2008-05-06)
ISBN: 037542430X
List Price: $25.95
Amazon Price: $12.95
Used Price: $14.99
Amgen net earnings climb 2 per cent, helped by arthritis med
New York - Amgen Inic, the world’s largest biotechnology company, Thursday reported a 2 per cent increase in first quarter profits compared to the same period last year, helped by the arthritis treatment Enbrel. Net income was 1.14 billion dollars, c…
The Cartoon Guide to Genetics (Updated Edition)
Having trouble deciphering your genetic code? Do dominant genes make you feel recessive? Let reigning nonfiction cartoonist Larry Gonick and microbiologist Mark Wheelis ease your way through Mendelian genetics, molecular biology, and the basics of genetic engineering. Gonick’s drawings range from a moderately detailed look at ribosomes in action to loony pictures of dancing scientists, talking peas, and opinionated fruit flies. Matthew Meselson, co-discoverer of the “one gene-one protein” principle, says, “it puts textbooks to shame”–and he’s right. –Mary Ellen Curtin
Author: Larry Gonick, Mark Wheelis
Paperback: 224 pages
Company: Collins (1991-08-14) (1991-08-14)
ISBN: 0062730991
List Price: $17.95
Amazon Price: $4.95
Used Price: $1.59
Genzyme posts quarterly profit vs loss
BOSTON (Reuters) - Biotechnology company Genzyme Corp reported a fourth-quarter profit on Wednesday, reversing a year-earlier loss, as sales of its drugs for rare diseases increased.
ImClone hires JP Morgan to weigh options: sources
PHILADELPHIA (Reuters) - Biotechnology company ImClone Systems Inc has hired JP Morgan Chase & Co to help it weigh a takeover offer from Bristol-Myers Squibb Co or a possible break-up of the company, sources familiar with the situation said on Thursday.
Calvin College - Academics - Biotechnology
Biotechnology is expected to be the #1 applied science of the 21st century. … But because biotechnology affects not only science but also social justice, …
Icahn challenges Biogen on effort to sell itself
NEW YORK (Reuters) - Investor Carl Icahn is disputing statements by Biogen Idec over the biotechnology company’s efforts to sell itself last year, stepping up pressure in a proxy fight that will come to a head later this month.
Share This